title: Anti-TNF-alpha therapy for orofacial granulomatosis: proceed with caution.
authors.forename: D R
authors.initials: DR
authors.lastname: Gaya
authors.forename: S
authors.initials: S
authors.lastname: Aitken
authors.forename: J
authors.initials: J
authors.lastname: Fennell
authors.forename: J
authors.initials: J
authors.lastname: Satsangi
authors.forename: A G
authors.initials: AG
authors.lastname: Shand
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002481:Cellulitis / Q000139:chemically induced; D003875:Drug Eruptions / Q000209:etiology; D004487:Edema / Q000139:chemically induced; D005157:Facial Pain / Q000139:chemically induced*; D005260:Female; D005334:Fever / Q000139:chemically induced; D051261:Granulomatosis, Orofacial / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab